WO2007008548A3 - Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders - Google Patents

Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders Download PDF

Info

Publication number
WO2007008548A3
WO2007008548A3 PCT/US2006/026272 US2006026272W WO2007008548A3 WO 2007008548 A3 WO2007008548 A3 WO 2007008548A3 US 2006026272 W US2006026272 W US 2006026272W WO 2007008548 A3 WO2007008548 A3 WO 2007008548A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disorders
treating
mitochondrial
insulin resistance
Prior art date
Application number
PCT/US2006/026272
Other languages
French (fr)
Other versions
WO2007008548A2 (en
Inventor
Michael Milburn
Jill Milne
Johan Auwerx
Carmen Argmann
Marie Lagouge
Michelle Dipp
Original Assignee
Sirtris Pharmaceuticals Inc
Michael Milburn
Jill Milne
Johan Auwerx
Carmen Argmann
Marie Lagouge
Michelle Dipp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirtris Pharmaceuticals Inc, Michael Milburn, Jill Milne, Johan Auwerx, Carmen Argmann, Marie Lagouge, Michelle Dipp filed Critical Sirtris Pharmaceuticals Inc
Priority to AU2006269459A priority Critical patent/AU2006269459B2/en
Priority to JP2008519734A priority patent/JP2009500357A/en
Priority to EP06786429A priority patent/EP1898897A2/en
Priority to CA002613141A priority patent/CA2613141A1/en
Publication of WO2007008548A2 publication Critical patent/WO2007008548A2/en
Publication of WO2007008548A3 publication Critical patent/WO2007008548A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)

Abstract

Provided herein are methods and compositions for treating or preventing metabolic disorders, such as obesity and diabetes. Methods may comprise modulating the activity or level of a sirtuin, such as SIRTl or Sir2. Exemplary methods comprise contacting a cell with a sirtuin activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin, or an inhibitory compound, such as nicotinamide.
PCT/US2006/026272 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders WO2007008548A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006269459A AU2006269459B2 (en) 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
JP2008519734A JP2009500357A (en) 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders and mitochondrial related disorders
EP06786429A EP1898897A2 (en) 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA002613141A CA2613141A1 (en) 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US69744305P 2005-07-07 2005-07-07
US60/697,443 2005-07-07
US73652805P 2005-11-14 2005-11-14
US60/736,528 2005-11-14
US75360605P 2005-12-23 2005-12-23
US60/753,606 2005-12-23
US78380206P 2006-03-16 2006-03-16
US60/783,802 2006-03-16

Publications (2)

Publication Number Publication Date
WO2007008548A2 WO2007008548A2 (en) 2007-01-18
WO2007008548A3 true WO2007008548A3 (en) 2007-08-09

Family

ID=37492426

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/026272 WO2007008548A2 (en) 2005-07-07 2006-07-07 Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders

Country Status (6)

Country Link
EP (1) EP1898897A2 (en)
JP (1) JP2009500357A (en)
CN (1) CN103055313A (en)
AU (1) AU2006269459B2 (en)
CA (1) CA2613141A1 (en)
WO (1) WO2007008548A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1853590A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
CN101296693B (en) * 2005-10-26 2012-07-04 花王株式会社 Endurance improver
US7718830B2 (en) 2006-04-24 2010-05-18 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
CA2648884C (en) 2006-04-24 2015-10-13 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US7618966B2 (en) 2006-04-24 2009-11-17 Allergan, Inc. Abnormal Cannabidiols as agents for lowering intraocular pressure
US7612101B2 (en) 2006-04-24 2009-11-03 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
US8802638B1 (en) * 2007-01-25 2014-08-12 University Of South Florida Flavonoid treatment of glycogen synthase kinase-based disease
US8778986B1 (en) * 2007-01-25 2014-07-15 University Of South Florida Treatment of glycogen synthase kinase-based disease
MX2009008022A (en) * 2007-01-26 2009-12-11 Univ Washington Methods and compositions for treating neuropathies.
EP2170338A2 (en) 2007-07-06 2010-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna-pkcs modulates energy regulation and brain function
EP2214698A2 (en) * 2007-10-23 2010-08-11 President and Fellows of Harvard College Use of compounds activating sirt-3 for mimicking exercise
MX2010012010A (en) 2008-05-01 2010-11-30 Sirtris Pharmaceuticals Inc Quenolines and related analogs as sirtuin modulators.
AU2009266889B2 (en) 2008-07-03 2013-05-02 Glaxosmithkline Llc Benzimidazoles and related analogs as sirtuin modulators
WO2010020959A1 (en) * 2008-08-21 2010-02-25 University Of Cape Town Resveratrol-containing composition for treating heart failure
CA2738809C (en) 2008-09-29 2015-11-24 Sirtris Pharmaceuticals, Inc. Quinazolinone, quinolone and related analogs as sirtuin modulators
JP5655243B2 (en) * 2009-10-19 2015-01-21 国立大学法人 熊本大学 Indoxyl sulfate production inhibitor screening method, indoxyl sulfate metabolic production inhibitor, and renal injury reducing agent
WO2011059839A1 (en) 2009-10-29 2011-05-19 Sirtris Pharmaceuticals, Inc. Bicyclic pyridines and analogs as sirtuin modulators
BR112012010587A2 (en) * 2009-11-06 2015-09-29 David Gladstone Inst methods and compositions for modulating tau levels.
JP5581071B2 (en) * 2010-02-03 2014-08-27 花王株式会社 Mitochondrial function improver
US8937055B2 (en) 2010-07-15 2015-01-20 Takeda Pharmaceutical Company Limited Heterocyclic ring compound having muscle cell or adipocyte differentiation regulating action
US9499790B2 (en) 2010-08-26 2016-11-22 Kyoto University Method for promoting differentiation of pluripotent stem cells into cardiac muscle cells
JP5930205B2 (en) * 2010-08-26 2016-06-08 国立大学法人京都大学 Promoting myocardial differentiation of pluripotent stem cells
JP5850503B2 (en) * 2010-09-14 2016-02-03 北海道公立大学法人 札幌医科大学 Composition for treating muscular dystrophy
AU2015201809B2 (en) * 2010-12-20 2016-09-29 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
EP2654452B1 (en) * 2010-12-20 2017-01-04 Hill's Pet Nutrition, Inc. Pet food compositions for inducing a satiety response
MX336980B (en) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combination and composition for treating obesity.
WO2012114204A2 (en) * 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
KR101451357B1 (en) * 2011-02-18 2014-10-15 주식회사 스템디알 Composition for preventing or treating sepsis or septic shock comprising SIRT1 expression inducer
WO2012145749A1 (en) * 2011-04-22 2012-10-26 Napo Pharmaceuticals, Inc. Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
WO2013002879A1 (en) * 2011-06-29 2013-01-03 President And Fellows Of Harvard College Small molecule cd38 inhibitors and methods of using same
JP6158801B2 (en) * 2011-07-15 2017-07-05 ニューサート サイエンシーズ， インコーポレイテッド Compositions and methods for modulating metabolic pathways
WO2013051459A1 (en) * 2011-10-02 2013-04-11 キユーピー 株式会社 Promoter capable of promoting inhibition of expression of mrna by rna interference, and use thereof
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
WO2013111875A1 (en) * 2012-01-27 2013-08-01 国立大学法人京都大学 Method for inducing differentiation of pluripotent stem cell into cardiac muscle
WO2014014828A1 (en) 2012-07-16 2014-01-23 Cornell University Nicotinamide riboside to treat hearing loss
WO2014014819A2 (en) * 2012-07-17 2014-01-23 Ngm Biopharmaceuticals, Inc. Methods of treating glucose metabolism disorders
WO2014014816A2 (en) * 2012-07-17 2014-01-23 Ngm Biopharmaceuticals, Inc. Methods of treating glucose metabolism disorders
SG10201709195TA (en) 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
EP2966166B1 (en) 2013-03-08 2019-04-03 Kyoto University Promoter of differentiation of pluripotent stem cell into myocardium, which comprises egf receptor inhibitor
CA2902879C (en) * 2013-03-15 2023-09-26 Nusirt Sciences, Inc. Leucine and nicotinic acid reduces lipid levels
CA2915163A1 (en) * 2013-06-12 2014-12-18 Proximagen Limited New therapeutic uses of enzyme inhibitors
US20160101072A1 (en) * 2013-06-12 2016-04-14 Proximagen Limited Therapeutic uses of enzyme inhibitors
EP3063163B1 (en) * 2013-10-30 2022-08-10 Chromadex Inc. Nicotinamide riboside compositions for topical use in treating skin conditions
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US10233426B2 (en) 2014-05-30 2019-03-19 Kyoto University Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds
US9370503B1 (en) * 2015-02-26 2016-06-21 Chi Chou Liao Compounds for treating ocular diseases
JP6545256B2 (en) * 2015-03-31 2019-07-17 新興和製薬株式会社 Food composition comprising resveratrol and nicotinamide mononucleotide
WO2017042198A2 (en) * 2015-09-08 2017-03-16 Ecole Polytechnique Federale De Lausanne (Epfl) Agents and methods using thereof for the prevention and treatment of stem cell muscle disorders
JP7182837B2 (en) * 2015-12-24 2022-12-05 アマゼンティス エスアー Compositions containing nicotinamide riboside and urolithins
WO2018002215A1 (en) * 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
CN109890376A (en) * 2016-10-27 2019-06-14 三得利控股株式会社 Composition is used in PGC-1 α activation
CN108066348A (en) * 2016-11-16 2018-05-25 成都普睿法药物研发有限公司 Application of the ponticin in anti-fibrosis drug is prepared
CN106580951B (en) * 2016-11-17 2019-07-30 珠海雅光生物工程有限公司 A kind of new application of flavanone compound
WO2018118197A1 (en) * 2016-12-21 2018-06-28 Richard Postrel Healthier aging in domesticated animals
JP2018172346A (en) * 2017-03-31 2018-11-08 株式会社東洋新薬 Pregnancy support composition
EP3388072A1 (en) * 2017-04-10 2018-10-17 Universität Leipzig Ubiquinone-independent cytoplasmic dihydroorotate dehydrogenase for use as medicament
JP7143402B2 (en) * 2017-05-17 2022-09-28 ウニベルシタ デ バレンシア－エストゥディ ヘネラル Treatment and prevention of motor neuron disease using nicotinamide riboside
CN109896997A (en) * 2017-12-08 2019-06-18 中国药科大学 The preparation method and its usage of N- anilid class c-Met kinase inhibitor
WO2019143560A1 (en) * 2018-01-16 2019-07-25 The Regents Of The University Of California Methods for promoting mitochondrial biogenesis in neural cells
MY196370A (en) * 2018-12-05 2023-03-27 Celagenex Res India Pvt Ltd Synergistic Compositions Of Bioactive Agents For Optimizing Cellular Health
KR20200068996A (en) * 2018-12-06 2020-06-16 한국화학연구원 Compound for inhibiting PDE9A and medical uses thereof
CN112516138B (en) * 2020-12-15 2022-03-29 中国人民解放军陆军军医大学 Application of compound YX-2102 in preparation of medicine for treating pulmonary fibrosis
US20230330124A1 (en) 2020-12-18 2023-10-19 Nuvamid Sa Nicotinamide mononucleotide derivatives and use thereof in the treatment and prevention of a red blood cell disorder
WO2022268047A1 (en) * 2021-06-22 2022-12-29 Nanjing Nutrabuilding Bio-Tech Co., Ltd Use of L-ergothioneine to ameliorate and prevent age-related vitreous degeneration
CN117580573A (en) * 2021-06-22 2024-02-20 南京纽邦生物科技有限公司 L-ergothioneine for the relief and prevention of age-related vision deterioration
CN113663083A (en) * 2021-08-16 2021-11-19 重庆第二师范学院 Fisetin phospholipid complex, weight-losing medicine/health food and application thereof
CN114668845B (en) * 2022-04-06 2023-04-11 北京清华长庚医院 Application of liver Sirt5 protein in preparation of product for inhibiting gluconeogenesis and improving glucose tolerance
CN114920805B (en) * 2022-05-06 2022-12-06 浙江湃肽生物股份有限公司 Novel scorpion venom having wrinkle-improving activity and composition comprising the same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032410A2 (en) * 2000-10-19 2002-04-25 Imperial College Innovations Limited Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
WO2002081651A2 (en) * 2001-02-20 2002-10-17 Uab Research Foundation Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
WO2003099040A1 (en) * 2002-05-27 2003-12-04 Advance Holdings Limited Dietary supplements from wine vinasses and relevant production process
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2005065667A2 (en) * 2003-12-29 2005-07-21 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2005069998A2 (en) * 2004-01-20 2005-08-04 Brigham Young University Technology Transfer Office Novel sirtuin activating compounds and methods for making the same
WO2005099761A1 (en) * 2004-04-07 2005-10-27 Resveratrol Partners, Llc Dietary supplement and method of processing same
WO2006076681A2 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001072583A (en) * 1999-09-07 2001-03-21 Sunstar Inc Prophylactic or therapeutic composition for hyperlipemia
PL2218342T3 (en) * 2003-05-27 2019-01-31 Dsm Ip Assets B.V. Novel nutraceutical compositions and use thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032410A2 (en) * 2000-10-19 2002-04-25 Imperial College Innovations Limited Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders
WO2002081651A2 (en) * 2001-02-20 2002-10-17 Uab Research Foundation Polyphenolics for enhancing endothelial cell-mediated fibrinolysis
WO2003099040A1 (en) * 2002-05-27 2003-12-04 Advance Holdings Limited Dietary supplements from wine vinasses and relevant production process
WO2005002555A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2005065667A2 (en) * 2003-12-29 2005-07-21 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
WO2005069998A2 (en) * 2004-01-20 2005-08-04 Brigham Young University Technology Transfer Office Novel sirtuin activating compounds and methods for making the same
WO2005099761A1 (en) * 2004-04-07 2005-10-27 Resveratrol Partners, Llc Dietary supplement and method of processing same
WO2006076681A2 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIEGANOWSKI PAWEL ET AL: "Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans", CELL, vol. 117, no. 4, 14 May 2004 (2004-05-14), pages 495 - 502, XP002410220, ISSN: 0092-8674 *
DEAN: "Resveratrol:clinical and anti-aging benefits", VITAMIN RESEARCH NEWS, vol. 18, no. 11, December 2004 (2004-12-01), pages 1-7, XP002411541 *
GESCHER ANDREAS J ET AL: "Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: A conundrum.", CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, vol. 12, no. 10, October 2003 (2003-10-01), pages 953 - 957, XP002411542, ISSN: 1055-9965 *
NISOLI ENZO ET AL: "Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS", SCIENCE (WASHINGTON D C), vol. 310, no. 5746, October 2005 (2005-10-01), pages 314 - 317, XP002411543, ISSN: 0036-8075 *
See also references of EP1898897A2 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527816B2 (en) 2005-05-10 2016-12-27 Intermune, Inc. Method of modulating stress-activated protein kinase system
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9359379B2 (en) 2012-10-02 2016-06-07 Intermune, Inc. Anti-fibrotic pyridinones

Also Published As

Publication number Publication date
EP1898897A2 (en) 2008-03-19
AU2006269459B2 (en) 2013-02-07
CN103055313A (en) 2013-04-24
WO2007008548A2 (en) 2007-01-18
AU2006269459A1 (en) 2007-01-18
JP2009500357A (en) 2009-01-08
CA2613141A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
WO2007008548A3 (en) Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
WO2006076681A3 (en) Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006079021A3 (en) Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
WO2005002555A3 (en) Sirt1 modulators for manipulating cell/organism lifespan/stress response
WO2005063232A8 (en) Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
WO2008011453A3 (en) SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
WO2007005453A3 (en) Compositions for treating or preventing obesity and insulin resistance disorders
WO2006096780A3 (en) Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2008080001A3 (en) Compounds and methods for kinase modulation, and indications therefor
WO2006105345A3 (en) Compositions and methods for the control, prevention, and treatment of obesity and eating disorders
WO2007126957A3 (en) New compounds
WO2008048991A3 (en) Organic compounds
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2007025090A3 (en) Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2006050162A3 (en) Imidazole derivatives
WO2007095601A3 (en) Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
WO2007024971A3 (en) Hedgehog pathway antagonists to treat disease
WO2006076442A3 (en) Triazolopyrimidine derivatives
WO2006099943A8 (en) Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
WO2009010139A3 (en) Quinazolinamide derivatives
WO2005116003A3 (en) Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof
WO2006120030A8 (en) Erythropoietin variants
WO2007145835A3 (en) Benzamide derivatives as modulators of 11beta-hsd1 for treating diabetes and obesity
WO2005118538A3 (en) Arylsulfonamides and uses as hydroxysteroid dehydrogenase
WO2007084162A3 (en) Sirtuin inhibiting compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680033014.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006269459

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2613141

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006786429

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008519734

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006269459

Country of ref document: AU

Date of ref document: 20060707

Kind code of ref document: A